Overview
PYC Therapeutics Limited is a biomedical company based in Australia, operating primarily within the biotechnology industry. The company is actively engaged in the development of novel therapies using its proprietary drug delivery platform, which focuses on targeting a range of inherited diseases at the genetic level. A key area of their research involves utilizing Phosphorodiamidate Morpholino Oligomers (PMO) to inhibit or modulate the expression of specific genes implicated in various genetic disorders. Notably, PYC Therapeutics is advancing several projects addressing ocular diseases, aiming to leverage its technology to develop effective treatments for conditions that currently lack adequate therapeutic options. By focusing on precise gene silencing techniques, PYC Therapeutics seeks to pioneer advancements in genetic medicine, offering hope for transformative treatments in areas of significant unmet medical need.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for PYC Therapeutics Limited as of 30 June 2025 is 23.49 MM.
- The operating income for PYC Therapeutics Limited as of 30 June 2025 is -53.63 MM.
- The net income for PYC Therapeutics Limited as of 30 June 2025 is -50.30 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 23.49 | -53.63 | -50.30 |
| 2025-03-31 | 24.24 | -51.87 | -49.25 |
| 2024-12-31 | 24.99 | -50.11 | -48.20 |
| 2024-09-30 | 23.52 | -44.49 | -42.96 |
| 2024-06-30 | 22.06 | -38.86 | -37.73 |
| 2024-03-31 | 21.65 | -30.39 | -29.69 |
| 2023-12-31 | 21.24 | -21.92 | -21.65 |
| 2023-09-30 | 18.52 | -22.68 | -22.22 |
| 2023-06-30 | 15.81 | -23.43 | -22.79 |
| 2023-03-31 | 14.66 | -24.08 | -23.24 |
| 2022-12-31 | 13.52 | -24.73 | -23.68 |
| 2022-09-30 | 14.78 | -19.51 | -18.77 |
| 2022-06-30 | 16.04 | -14.29 | -13.86 |
| 2022-03-31 | 12.56 | -15.85 | -15.34 |
| 2021-12-31 | 9.07 | -17.42 | -16.82 |
| 2021-09-30 | 6.07 | -18.09 | -17.29 |
| 2021-06-30 | 3.07 | -18.76 | -17.77 |
| 2021-03-31 | 2.74 | -14.85 | -14.93 |
| 2020-12-31 | 2.40 | -10.95 | -12.09 |
| 2020-09-30 | 2.40 | -9.13 | -9.46 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | -0.11 | -0.11 |
| 2024-09-30 | -0.10 | -0.10 |
| 2024-06-30 | -0.10 | -0.10 |
| 2024-03-31 | -0.08 | -0.08 |
| 2023-12-31 | -0.06 | -0.06 |
| 2023-09-30 | -0.07 | -0.07 |
| 2023-06-30 | -0.07 | -0.07 |
| 2023-03-31 | -0.07 | -0.07 |
| 2022-12-31 | -0.07 | -0.08 |
| 2022-09-30 | -0.06 | -0.06 |
| 2022-06-30 | -0.04 | -0.04 |
| 2022-03-31 | -0.05 | -0.05 |
| 2021-12-31 | -0.05 | -0.05 |
| 2021-09-30 | -0.06 | -0.05 |
| 2021-06-30 | -0.06 | -0.06 |
| 2021-03-31 | -0.05 | -0.05 |
| 2020-12-31 | -0.04 | -0.04 |
| 2020-09-30 | -0.03 | -0.03 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for PYC Therapeutics Limited as of 30 June 2025 is -51.56 MM.
- The cash from investing activities for PYC Therapeutics Limited as of 30 June 2025 is -0.98 MM.
- The cash from financing activities for PYC Therapeutics Limited as of 30 June 2025 is 138.66 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -51.56 | -0.98 | 138.66 |
| 2025-03-31 | -50.16 | -0.88 | 105.71 |
| 2024-12-31 | -48.77 | -0.78 | 72.76 |
| 2024-09-30 | -43.68 | -0.54 | 81.48 |
| 2024-06-30 | -38.59 | -0.31 | 90.19 |
| 2024-03-31 | -28.99 | -0.47 | 59.50 |
| 2023-12-31 | -19.38 | -0.63 | 28.81 |
| 2023-09-30 | -21.90 | -0.55 | 20.12 |
| 2023-06-30 | -24.42 | -0.48 | 11.44 |
| 2023-03-31 | -25.23 | 10.61 | 5.63 |
| 2022-12-31 | -26.04 | 21.69 | -0.17 |
| 2022-09-30 | -23.91 | 27.18 | -0.18 |
| 2022-06-30 | -21.78 | 32.68 | -0.18 |
| 2022-03-31 | -17.36 | 30.55 | -0.05 |
| 2021-12-31 | -12.95 | 28.43 | 0.09 |
| 2021-09-30 | -12.37 | 6.45 | 19.32 |
| 2021-06-30 | -11.79 | -15.52 | 38.56 |
| 2021-03-31 | -11.04 | -19.94 | 38.42 |
| 2020-12-31 | -10.29 | -24.35 | 38.29 |
| 2020-09-30 | -8.02 | -19.06 | 31.70 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for PYC Therapeutics Limited as of 30 June 2025 is -15.67.
- The p/book for PYC Therapeutics Limited as of 30 June 2025 is 13.56.
- The p/tbv for PYC Therapeutics Limited as of 30 June 2025 is 14.67.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -15.67 | 13.56 | 14.67 |
| 2025-03-31 | -14.29 | 12.36 | 13.31 |
| 2024-12-31 | -16.94 | 7.89 | 8.30 |
| 2024-09-30 | -9.89 | 4.61 | 4.85 |
| 2024-06-30 | -13.10 | ||
| 2024-03-31 | -13.10 | ||
| 2023-12-31 | -18.02 | 14.44 | 16.97 |
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | -16.84 | 5.95 | 6.57 |
| 2021-12-31 | -24.17 | 7.96 | 8.71 |
| 2021-09-30 | -25.06 | 8.26 | 9.04 |
| 2021-06-30 | -13.25 | 4.37 | 4.78 |
| 2021-03-31 | -15.72 | 4.35 | 4.76 |
| 2020-12-31 | -19.41 | 3.82 | 4.14 |
| 2020-09-30 | -22.94 | 3.53 | 3.82 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for PYC Therapeutics Limited as of 30 June 2025 is -0.07.
- The ebit (3y)/ev for PYC Therapeutics Limited as of 30 June 2025 is -0.05.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.07 | -0.05 |
| 2025-03-31 | -0.08 | -0.05 |
| 2024-12-31 | -0.07 | -0.05 |
| 2024-09-30 | -0.12 | -0.09 |
| 2024-06-30 | -0.08 | -0.03 |
| 2024-03-31 | -0.08 | -0.03 |
| 2023-12-31 | -0.06 | -0.05 |
| 2023-09-30 | -0.12 | -0.09 |
| 2023-06-30 | -0.14 | -0.11 |
| 2023-03-31 | -0.13 | -0.10 |
| 2022-12-31 | -0.07 | -0.07 |
| 2022-09-30 | -0.08 | -0.08 |
| 2022-06-30 | -0.09 | -0.08 |
| 2022-03-31 | -0.07 | -0.05 |
| 2021-12-31 | -0.05 | -0.03 |
| 2021-09-30 | -0.04 | -0.03 |
| 2021-06-30 | -0.09 | -0.05 |
| 2021-03-31 | -0.07 | -0.05 |
| 2020-12-31 | -0.05 | -0.04 |
| 2020-09-30 | -0.04 | -0.04 |
Management Effectiveness
- The roa for PYC Therapeutics Limited as of 30 June 2025 is -0.53.
- The roe for PYC Therapeutics Limited as of 30 June 2025 is -0.62.
- The roic for PYC Therapeutics Limited as of 30 June 2025 is -0.85.
- The croic for PYC Therapeutics Limited as of 30 June 2025 is 0.42.
- The ocroic for PYC Therapeutics Limited as of 30 June 2025 is -0.86.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.53 | -0.62 | -0.85 | 0.42 | -0.86 |
| 2025-03-31 | -0.53 | -0.59 | -0.85 | 0.42 | -0.86 |
| 2024-12-31 | -0.95 | -1.57 | -0.46 | 0.62 | -0.47 |
| 2024-09-30 | -0.95 | -1.40 | -0.46 | 0.62 | -0.47 |
| 2024-06-30 | -0.68 | ||||
| 2024-03-31 | -0.68 | ||||
| 2023-12-31 | -0.72 | -0.96 | -0.77 | -0.09 | -0.76 |
| 2023-09-30 | -0.50 | -0.57 | -0.79 | -0.47 | -0.85 |
| 2023-06-30 | -0.52 | -0.57 | -0.79 | -0.47 | -0.85 |
| 2023-03-31 | -0.52 | -0.58 | -0.81 | -0.31 | -0.88 |
| 2022-12-31 | -0.27 | -0.39 | -0.79 | 0.13 | -1.01 |
| 2022-09-30 | -0.27 | -0.39 | -0.79 | 0.13 | -1.01 |
| 2022-06-30 | -0.29 | -0.26 | -0.34 | 0.26 | -0.53 |
| 2022-03-31 | -0.29 | -0.28 | -0.37 | 0.32 | -0.42 |
| 2021-12-31 | -0.28 | -0.27 | -0.35 | 0.32 | -0.22 |
| 2021-09-30 | -0.27 | -0.28 | -0.36 | 0.28 | -0.22 |
| 2021-06-30 | -0.56 | -0.59 | -0.33 | 0.20 | -0.22 |
| 2021-03-31 | -0.47 | -0.49 | -0.27 | 0.13 | -0.20 |
| 2020-12-31 | -0.34 | -0.35 | -0.19 | 0.06 | -0.17 |
| 2020-09-30 | -0.26 | -0.27 | -0.15 | 0.07 | -0.13 |
Gross Margins
- The gross margin for PYC Therapeutics Limited as of 30 June 2025 is 1.00.
- The net margin for PYC Therapeutics Limited as of 30 June 2025 is -1.93.
- The operating margin for PYC Therapeutics Limited as of 30 June 2025 is -2.01.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 1.00 | -1.93 | -2.01 |
| 2025-03-31 | 1.00 | -1.93 | -2.01 |
| 2024-12-31 | 1.00 | -1.71 | -1.76 |
| 2024-09-30 | 1.00 | -1.71 | -1.76 |
| 2024-06-30 | 1.00 | -1.44 | -1.48 |
| 2024-03-31 | 1.00 | -1.44 | -1.48 |
| 2023-12-31 | 1.00 | -1.44 | -1.48 |
| 2023-09-30 | 1.00 | -1.44 | -1.48 |
| 2023-06-30 | 1.00 | -1.44 | -1.48 |
| 2023-03-31 | 1.00 | -1.58 | -1.64 |
| 2022-12-31 | 1.00 | -1.27 | -1.32 |
| 2022-09-30 | 1.00 | -1.27 | -1.32 |
| 2022-06-30 | 1.00 | -0.86 | -0.89 |
| 2022-03-31 | 1.00 | -1.22 | -1.26 |
| 2021-12-31 | 1.00 | -1.85 | -1.92 |
| 2021-09-30 | 1.00 | -2.85 | -2.98 |
| 2021-06-30 | 0.31 | -5.78 | -6.10 |
| 2021-03-31 | -0.35 | -9.53 | -10.23 |
| 2020-12-31 | -71.39 | -5.05 | -5.55 |
| 2020-09-30 | -112.57 | -324.14 | -393.94 |
Identifiers and Descriptors
| Central Index Key (CIK) |
